Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
Would you offer adjuvant therapy to stage IIIB Cecal medullary carcinoma that is MMR- proficient?
Related Questions
Would you use triplet chemotherapy FLOT in lieu of chemoRT for patients with localized esophageal squamous cell carcinoma?
How do you integrate immunotherapy as a part of neoadjuvant treatment for MSI high stage III gastric carcinoma?
In an N+ rectal adenocarcinoma treated via PROSPECT with neoadjuvant FOLFOX with omission of CRT and no treatment response in the primary on pathology (ypN+), would you offer adjuvant chemotherapy or chemo-radiation?
Would you recommend radiation or chemoradiation in a patient with cholangiocarcinoma s/p surgery and adjuvant treatment with single hepatic metastasis 3 years later?
What systemic therapy would you use in T3N1M1 MMR proficient rectal cancer with solitary liver lesion when going for curative intent (chemo>short course RT> resection of primary and liver met)?
With recent PFS data from LEAP-012 and Emerald-1, do you routinely offer for patients with intermediate BCLC stage HCC undergoing TACE or TARE systemic therapy (pembro/lenva or durve/bev)?
What is the data to guide salvage radiation to a patient with recurrence anal cancer to the lymph node after an initial definitive chemoradiation?
What factors would make you choose IPI3/NIVO1 frontline for advanced unresectable and metastatic HCC based on CheckMate 9DW?
What factors do you consider when deciding between dual vs single-agent immunotherapy for patients with MSI-H or dMMR metastatic CRC?
In patients with cholangiocarcinoma who qualify for HAIP therapy, would you recommend treating with chemotherapy and immunotherapy?
